IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma June 7, 2017 ASCO/EHA Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001) June 7, 2017 ASCO/EHA Impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease June 5, 2017 ASCO/EHA Phase 3 ELOQUENT-2 study: Elotuzumab plus lenalidomide/dexamethasone vs Ld in relapsed/refractory multiple myeloma (RRMM) June 4, 2017 ASCO/EHA CheckMate 602: A phase 3 trial of combinations of nivo, elo, pom and dex in RRMM June 3, 2017 ASCO/EHA Dr. David Tamborero on the landscape of lesions in myeloma & consequences for targeted drug response (ASH 2014) October 15, 2015 ASCO/EHA ASCO 2014: Free light chain assay and cytogenetic abnormalities for identification of HRSM October 13, 2015 ASCO/EHA ASCO 2014: Survival benefit and cost of Auto HSCT in elderly patients with MM October 13, 2015 ASCO/EHA ASCO 2014: Continuous treatment versus fixed duration of therapy in newly diagnosed myeloma patients October 13, 2015 ASCO/EHA ASCO 2014: E1A06: A phase III trial comparing MPT versus MPR in newly diagnosed multiple myeloma October 13, 2015 ASCO/EHA
